Arbutus Biopharma (ABUS) received a Notice of Allowance for its US patent application 16/312,162 titled "COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA" - Patent Grants
- Wall Street closes rollercoaster week sharply lower
- Invesco (IVZ) Reportedly in Talks to Merge With State Street's (STT) Asset Management Business, Citi Sees More Cons than Pros
- FDA Votes "No" on Pfizer (PFE) Booster for 16+ Age Group, 2 Yes 16 No
- Jefferies Raises Price Targets on Alphabet (GOOGL) and Facebook (FB) as They Are Still Inexpensive Relative to Growth, Reiterates Snap (SNAP) as a Best Growth Idea
- Tesla (TSLA) Could Deliver 900K EV Units This Year and 1.3M in 2022 - Wedbush
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Arbutus Biopharma (NASDAQ: ABUS) received a Notice of Allowance for its US patent application 16/312,162 titled "COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA" - Patent Grants
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: FDA Approves Exelixis's (EXEL) CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
- Intermedia Cloud Communications (INTM) Files For Up to $100M IPO
- GitLab Inc (GTLB) Files For up to $100M IPO
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!